NCT05413824 (NEU-COVID) is a clinical trial in COVID-19, sponsored by Centre Hospitalier Universitaire de Nīmes.

Who is sponsoring NCT05413824?

NCT05413824 is sponsored by Centre Hospitalier Universitaire de Nīmes.

Is NCT05413824 still recruiting?

NCT05413824 is currently completed. Last updated 4 December 2025.

Last reviewed 2025-12-04 · How we verify

NCT05413824: NEU-COVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neutrophil Side Fluorescent Light (NEU-SFL) in COVID-19 Patients

Completed Last updated 4 December 2025

What this trial tests

trial in COVID-19 in 2,233 participants. Completed in 31 December 2022.

Timeline

2 June 2022

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nīmes
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,233
Start date	2 June 2022
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across France

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Centre Hospitalier Universitaire de Nīmes

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recently, a study showed that markers of neutrophil extracellular traps formation, a mechanism corresponding to neutrophil activation, were increased in patients who died of COVID 19 compared with survivors. The investigators propose to analyze the NEU-SFL parameter, obtained automatically on the Sysmex™ blood count machine (Sysmex Corporation, Kobe, Japan) and which is considered as a reflect of neutrophil extracellular traps formation, in these two groups of patients. The aim was to evaluate whether this parameter could be used to predict the risk of death related to COVID 19.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Direct blood fluorescence signal intensity of neutrophils (NEU-SFL): A predictive marker of death in hospitalized COVID-19 patients?
Fortier M, Chea M, Aïn C, Loyens M, et al · · 2022 · cited 2× · PMID 36619613 · DOI 10.3389/fmed.2022.1062112

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Centre Hospitalier Universitaire de Nīmes trials

Trials by the same sponsor.

NCT07403474 — Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Ther · Phase 4 · not yet recruiting
NCT07455981 — Work Organization and Gambling Addiction · not yet recruiting
NCT07403500 — Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain. · NA · not yet recruiting
NCT07342010 — Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT · Phase 4 · not yet recruiting
NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05413824 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nīmes
Last refreshed: 4 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05413824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing